Marlène H. W. van de Poel

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial

Pascale Notten, Arina J. ten Cate‐Hoek, Carsten W. K. P. Arnoldussen et al. · The Lancet Haematology · 2019 · 219 citations · Full text

Medicine, Cardiology, Hemostasis +12

Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial

Arina J. ten Cate‐Hoek, Elham E Amin, A.C. Bouman et al. · The Lancet Haematology · 2017 · 98 citations · Full text

Medicine, Surgery, Vascular Surgery +5

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · European Journal of Cancer · 2018 · 90 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

CAVA (Ultrasound‐Accelerated Catheter‐Directed Thrombolysis on Preventing Post‐Thrombotic Syndrome) Trial: Long‐Term Follow‐Up Results

Pascale Notten, A.A.E.A. de Smet, Lidwine W. Tick et al. · Journal of the American Heart Association · 2021 · 74 citations · Full text

Medicine, Surgery, Interventional Cardiology +15